Zogenix Inc. is attempting to raise $90 million through an initial public offering.
The San Diego-based company said it plans utilize the new funds to help commercialize its Sumavel DosePro drug-device combination and the clinical advancement of its ZX002 drug in a Securities & Exchange Commission filing.
